36
April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate Professor of Medicine Division of Infectious Diseases University of Washington, Seattle

April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

Embed Size (px)

Citation preview

Page 1: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

DHS/HIV/ARV Rx/PP

HIV/AIDS Opportunistic Infection Update

David H. Spach, MD

Medical DirectorNorthwest AIDS Education and Training Center

Associate Professor of MedicineDivision of Infectious Diseases

University of Washington, Seattle

Page 2: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

DHS/HIV/ARV RX/PP

Opportunistic Infection: Update

Pneumocytis pneumonia

Toxoplasmosis

Mycobacterium avium complex

Cytomegalovirus

Esophageal candidiasis

Cryptococcal meningitis

Cryptosporidiosis

Page 3: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

DHS/HIV/PP

Pneumocystis Pneumonia

Page 4: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Pneumocystis PneumoniaNew Developments

Basic Science- Pneumocystis carinii changed to Pneumocystis jiroveci* - Characterization of 14- demethylase enzyme

Epidemiology- Reactivation of latent organisms versus acute acquisition

New Diagnostics- PCR-based test on oral washes

Resistance to TMP-SMX- Mutations identified in dihydropterate synthase (DHPS)- Presence of mutation associated with increased mortality

Immune Reconstitution- Marked inflammatory response about 15-30 days after HAART

DHS/HIV/Clin Manifestations/PP

*Pronounced “yee row vet zee” & named after the Czech pathologist Otto Jirovec

Page 5: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Pneumocystis: Lanosterol 14- Demethylase

Ergosterol BiosynthesisLanosterol 14- Demethylase (Erg 11)

Ergosterol

Cytoplasmic Membrane

From: Morales IJ, et al. Am J Respir Mol Bio 2003;Feb 26 (e-Publication).

Inherent Azole Resistance

Page 6: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003DHS/ HIV/PP

Pneumocystis in Asymptomatic Individuals

Methods- N = 16 HIV-infected patients- BAL samples (n = 47)- Genotyping of P. jiroveci

Results- 35/47 from patients positive for P. jiroveci - 7 with P. jiroveci 7-10 months after acute PCP; all 7 had different genotype at follow-up than found during acute PJP- TMP-SMX did not always clear infection

From: Wakefield AE et al. J Infect Dis 2003;187:901-8.

Page 7: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Discontinuation of PCP ProphylaxisRecommendations from USPHS/IDSA Guidelines

DHS/HIV/OIs/PP

Setting

Primary Prophylaxis

Secondary Prophylaxis

CD4 > 200 for > 3 months

CD4 > 200 for > 3 months

Criteria

From: MMWR 2001;50 (RR-11):1-52.

Page 8: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003DHS/ HIV/PP

Pneumocystis & Immune Reconstitution

Timing- Typically 7 to 30 days after starting HAART

Clinical Manifestations- High grade-fever- Patchy infiltrates- BAL: few Pneumocystis organisms, severe inflammatory foci

Treatment- Restart corticosteroids

From: Wislez M et al. Am J Respir Crit Care Med 2001;164:847-51.

Page 9: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

DHS/HIV/PP

Toxoplasmosis

Page 10: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Discontinuation of Toxoplasmosis ProphylaxisRecommendations from USPHS/IDSA Guidelines

Setting

Primary Prophylaxis

Secondary Prophylaxis

CD4 > 200 for > 3 months

CD4 > 200 for > 6 months

and

Completed Initial Rx

and

Asymptomatic for Toxo

Criteria

From: MMWR 2001;50 (RR-11):1-52. DHS/HIV/OIs/PP

Page 11: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

DHS/HIV/PP

Mycobacterium avium Complex

Page 12: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

MAC: Immune Reconstitution Syndrome

DHS/ID/Cases/PP

• Low CD4 (< 50): more severe illness; fevers, weight loss, leukocytosis, positive blood cultures (Race, Lancet, 1998)

• High CD4 (> 100-150): fewer systemic symptoms, more localized suppurative disease (Phillips, JAIDS, 1998)

• Treatment: continue HAART and MAC therapy, NSAIDS, steroids (for severe symptoms), local surgery?

Slide From Bob Harrington, MD

Page 13: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Discontinuation of MAC ProphylaxisRecommendations from USPHS/IDSA Guidelines

Setting

Primary Prophylaxis

Secondary Prophylaxis

CD4 > 100 for > 3 months

CD4 > 100 for > 6 months

and

Completed 12 months MAC RX

and

Asymptomatic for MAC

Criteria

From: MMWR 2001;50 (RR-11):1-52. DHS/HIV/OIs/PP

Page 14: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

DHS/HIV/PP

Cytomegalovirus

Page 15: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003DHS/OIs/HIV

Valganciclovir (Valcyte) Induction Therapy for CMV Retinitis

90%

0

20

40

60

80

100

No

n-p

rog

ress

or

%

Valganciclovir (PO) Ganciclovir (IV)

90%

Methods - N = 160 - Newly diagnosed CMV retinitis

Regimens - Valganciclovir: 900 mg PO bid x 21d, 900 mg PO qd x 7d - Ganciclovir: 5 mg/kg IV bid x 21d, 5 mg/kg IV qd x 7d

Study Design Week 4: Non-progression

From: Martin DF et al. N Engl J Med 2002;346:1119-26.

Page 16: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Discontinuation of CMV ProphylaxisRecommendations from USPHS/IDSA Guidelines

Setting

Primary Prophylaxis

Secondary Prophylaxis

Not Applicable

CD4 > 100-150 for > 6 months

and

No evidence of active disease

and

Regular ophtho examinations

Criteria

From: MMWR 2001;50 (RR-11):1-52. DHS/HIV/OIs/PP

Page 17: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

DHS/HIV/PP

Esophageal Candidiasis

Page 18: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Fluconazole: Mechanism of Action

Fluconazole

Ergosterol BiosynthesisLanosterol 14- Demethylase

Ergosterol

Cytoplasmic Membrane

Page 19: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Fluconazole: Mechanism of Resistance

Fluconazole

Ergosterol BiosynthesisLanosterol 14- Demethylase

Ergosterol

Efflux Pump

Altered Binding Site

Fluconazole

Page 20: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Caspofungin: Mechanism of Action

Cell WallCytoplasmic Membrane

Glucan Fibrils

Beta-Glucan Synthase Beta-Glucan SynthaseEchinocandins

Page 21: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Fluconazole-Resistant Esophageal CandidiasisTreatment Options

Fluconazole (Diflucan) 400-800 mg PO qd

Itraconazole Solution (Sporonox) 100 mg PO bid

Caspofungin (Cancidas) 50-70 mg IV qd

Amphotericin B 0.3-0.7 mg/kg IV qd

Liposomal Ampho B ? Optimal Dose

DHS/HIV/OIs/PP

Drug Dose

Page 22: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Candida Species: In Vitro Testing

C. albicans

- Fluconazole (S)

- Fluconazole (R)

C. glabrata

- Fluconazole (S)

- Fluconazole (R)

DHS/HIV/OIs/PP

0.16

40

1.25

40

Organism Fluconazole (MIC 50)

0.20

0.20

0.20

0.40

Caspofungin (MIC 50)

From: Vazquez JA et al. Antimicrob Agents Chemo 1997;41:1612-4.

Page 23: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

DHS/OIs/HIV

Caspofungin (Cancidas) vs. AmphotericinTreatment of Esophageal Candidiasis

85%

96%

72% 74%

89%

63%

0

20

40

60

80

100

Fa

vo

rab

le R

es

po

ns

e

End of Rx 14 Day Post Rx

Caspofungin 50 mg

Caspofungin 70 mg

Amphotericin B

Methods

- N = 128 (123 HIV-infected*)

-*Mean CD4 = 84 cells/mm3

- Documented Candida esophagitis

- Randomized, double-blind study

Regimens (14 days)

- Caspofungin: 50 mg IV qd

- Caspofungin: 70 mg IV qd

- Amphotericin B: 0. 5 mg/kg IV qd

Study Design Clinical & Endoscopic Response (ITT)

From: Villanueva A et al. Clin Infect Dis 2001;33:1529-35.

Page 24: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

DHS/OIs/HIV

Fluconazole-Resistant Esophageal CandidiasisTreatment with Caspofungin

0

20

40

60

80

100

Cli

nic

al

Res

po

ns

e

Caspofungin

79%

Methods - N = 14 - Esophageal candidiasis - Failed Fluconazole 200 mg/d or - Isolate with Fluconazole MIC > 16

Regimens - Caspofugin

Response - Defined as resolution of all symptoms and substantial improvement on endoscopy

Study Design Clinical Response

From: Kartsonis NK et al. J Acquir Immune Defic Syndr 2002;31:183-7.

Page 25: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

DHS/HIV/PP

Cryptococcal Meningitis

Page 26: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Cryptococcal Meningitis: 14-Day Induction Therapy

DHS/OI/PP

Initial LP: Reduce opening pressure by 50%Daily LPs: Maintain opening < 200 mm H2OCessation of LPs: once opening pressure normal for several consecutive days

Ampho B0.7-1.0 mg/kg/d

+5-Flucytosine100 mg/kg/d

Suspected or Confirmed Cryptococcal Meningitis*Serial LPs if Opening Pressure > 200 mm H2O

Ampho B0.7-1.0 mg/kg/d

Fluconazole400-800 mg/d

2 31

Page 27: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Cryptococcal Meningitis: 10 Week Consolidation Therapy

DHS/OI/PP

Itraconazole400 mg/d

Cryptococcal Meningitis2 Week Lumbar Puncture with Negative Culture

Ampho B0.7-1.0 mg/kg/d

Fluconazole400 mg/d

2 31

Page 28: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003DHS/OIs/HIV

Cryptococcal MeningitisCSF Pressure Post-Treatment & Outcome

4%

20%

0

5

10

15

20

25

30

Clin

ical

Fai

lure

CSF Pressure: Decrease > 10

CSF Pressure: No Change CSF Pressure: Increase > 10

2%

Methods - N = 161 - HIV-infected - Cryptococcal meningitis - Retrospective analysis - Week 2 outcome - Compared pre/post CSF OP

Baseline - 60% > 250 mm H2O - 30% > 350 mm H2O

Study Design Week 2 Outcome: Clinical Failure

From: Graybill JR et al. Clin Infect Dis 2000;30:47-54.

Page 29: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003DHS/OIs/HIV

Cryptococcal MeningitisFeatures of High (> 350 mm H2O) CSF Pressure

Clinical Features - More frequent headache & meningismus - More frequent papilledema & abnormal reflexes

Lab Features - Higher CSF Cryptococcal antigen - More frequent positive India ink

Outcome Features - Reduced short-term survival if CSF pressure > 250

From: Graybill JR et al. Clin Infect Dis 2000;30:47-54.

Page 30: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003DHS/OIs/HIV

Cryptococcal MeningitisStrategies for Reducing High CSF Pressure

Lumbar Puncture - 18 gauge needle - Drained until CSF pressure < 200 mm H2O - Repeat as often as needed

Medical Therapy - Corticosteroids? - Acetazolamide? - Mannitol?

From: Graybill JR et al. Clin Infect Dis 2000;30:47-54.

Page 31: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003DHS/OIs/HIV

Cryptococcal MeningitisAcetazolamide for Reducing High CSF Pressure

Background - N = 22 Thai HIV-infected - Confirmed cryptococcal meningitis - CSF pressure > 200 mm H2O - Randomized, placebo-controlled

Regimens - Acetazolamide versusPlacebo

Results - No benefit, trial stopped secondary adverse effects

From: Newton PN et al. Clin Infect Dis 2002;35:769-72.

Page 32: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

DHS/HIV/PP

Cryptosporidiosis

Page 33: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Cryptosporidiosis in HIV/AIDSCombination Therapy

Study Design- N = 13- CD4 count < 100 cells/mm3 (median 30 cells/mm3) - Chronic cryptosporidiosis (median duration 12 weeks)

Regimen- Paromomycin 1g bid + Azithromycin 600 mg qd x 28d followed by Paromomycin 1g bid x 12 weeks

From:Smith NH et al. J Infect Dis 1998;178:900-3. DHS/HIV/Clin Manifestations/PP

Page 34: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

Cryptosporidiosis: Combination Therapy

Stool Frequency Oocyst Excretion

6.5

4.9

3.0

0

2

4

6

8

Sto

ols

/Day

Baseline

Week 4

Week 12

43

7.3 3.00

10

20

30

40

50

24-h

Oo

cyst

s x

106

Baseline

Week 4

Week 12

From: Smith NH et al. J Infect Dis 1998;178:900-3. DHS/HIV/OIs/PP

Page 35: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003DHS/OIs/HIV

Cryptosporidiosis:Nitazoxanide Therapy

80%

41%

67%

22%

0

20

40

60

80

100

Res

po

nse

%

Diarrhea Resolved Oocysts Cleared

Nitazoxanide Placebo Methods - N = 100 (50 adults, 50 children) - Cryptosporidiosis diarrhea - HIV testing not performed

Regimens* - Nitazoxanide: 500 mg bid x 3d - Placebo: bid x 3d

Study Design Response

From: Rossignol J-F et al. J Infect Dis 2001;184:103-6.

Children- Age 4-11 yrs: 200 mg bid x 3d- Age 1-3 yrs: 100 mg bid x 3d

Page 36: April 2003 DHS/HIV/ARV Rx/PP HIV/AIDS Opportunistic Infection Update David H. Spach, MD Medical Director Northwest AIDS Education and Training Center Associate

April 2003

DHS/HIV/ARV RX/PP

Cryptosporidiosis: Treatment

• HAART

• Antimicrobial Agents- Paromomycin- Azithromycin- Nitazoxanide

• Antimotility Agents

From: Chen X-M, et al. N Engl J Med 2002;346;1723-31.